Figure 2.

Osimertinib induces tumor regression in wild-type HER2 GEMMs.

A, Representative MRI image of HW mice before and after treatment with vehicle, erlotinib, osimertinib, or afatinib for 4 weeks. B, Waterfall plots show tumor volume change compared with before treatment, and each column represents one individual mouse. C, HW mice were treated with vehicle, osimertinib (Osi), or erlotinib (Erl) for 3 days, and tumor nodules were collected and lysates used in Western blot to detect pHER2 and downstream signaling. Two representative tumor samples from each group are shown.